C - Chemistry – Metallurgy – 12 – P
Patent
C - Chemistry, Metallurgy
12
P
C12P 21/08 (2006.01) A61K 39/395 (2006.01) A61P 35/00 (2006.01) C07K 16/18 (2006.01) C07K 16/30 (2006.01) C07K 16/46 (2006.01) C12N 5/16 (2006.01) G01N 33/567 (2006.01) G01N 33/574 (2006.01)
Patent
CA 2617458
The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.
L'invention se rapporte à une méthode permettant de produire des anticorps capables de modifier l'évolution d'une maladie cancéreuse chez un patient à l'aide d'un nouveau paradigme de criblage. Le procédé, qui consiste à isoler des anticorps anticancéreux en utilisant la cytotoxicité des cellules cancéreuses pour résultat final, permet de produire des anticorps anticancéreux destinés à un usage thérapeutique et diagnostique. On peut utiliser ces anticorps pour stadifier et diagnostiquer un cancer, et pour traiter des tumeurs primaires et des métastases tumorales. Ces anticorps anticancéreux peuvent être conjugués à des toxines, des enzymes, des composés radioactifs et des cellules hématogènes.
Cechetto Lisa M.
Hahn Susan E.
Young David S. F.
Arius Research Inc.
F.hoffmann-La Roche Ag
Gowling Lafleur Henderson Llp
LandOfFree
Cancerous disease modifying antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cancerous disease modifying antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancerous disease modifying antibodies will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1785326